{"filings":[{"id":2494478,"accession_number":"0001213900-26-094001","cik":2070887,"company_name":"Crown Reserve Acquisition Corp. I","ticker":"CRAC","form_type":"8-K","filed_at":"2026-08-26T20:37:44+00:00","items":["1.01","9.01"],"status":"ready","headline":"Crown Reserve and Carvix amend business combination agreement to clarify voting thresholds and executive salaries","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Aug 26, 2026, Crown Reserve, Merger Sub, and Carvix amended the March 30, 2026 Business Combination Agreement.","Amendment restates Section 5.04: business combination, Nasdaq, incentive plan, advisory, and adjournment proposals need simple majority of Class A and B shares.","Domestication and organizational documents proposals require two-thirds vote of Class B shares only; Class A has no vote on those.","Director election proposal requires simple majority of Class B shares only.","Base salaries for certain Carvix executives revised per Annex A; annual bonus calculated as percentage of new base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":262660000.00000003,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97569,"accession_number":"0001213900-26-040025","cik":2070887,"company_name":"Crown Reserve Acquisition Corp. I","ticker":"CRAC","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Crown Reserve (CRAC) enters definitive business combination with Carvix","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SPAC merges with Carvix via domestication to Delaware; Carvix management team continues leading combined company.","Carvix stockholders receive 50,000,001 shares at closing and up to 50,000,100 earnout shares tied to EBITDA and revenue targets.","Sponsor may earn up to 3,000,000 additional shares over three years based on annual milestones.","Post-closing board: five members, four nominated by Carvix (including one independent approved by Sponsor) and one by Sponsor.","Conditions include SPAC stockholder approval, effective S-4, Nasdaq listing, and minimum cash; outside date September 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":262660000.00000003,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97568,"accession_number":"0001213900-26-038670","cik":2070887,"company_name":"Crown Reserve Acquisition Corp. I","ticker":"CRAC","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Crown Reserve SPAC announces $1.0B business combination with Carvix","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction values Carvix at $1.0B implied enterprise value; all-stock at $10.00/share reference price.","Minimum $80M PIPE plus $20M committed equity line; requires $10M cash post-redemptions at close.","Carvix stockholders eligible for up to 50M earnout shares tied to revenue and EBITDA targets through 2030.","Post-closing board: 5 members (4 from Carvix, 1 from Sponsor); Carvix management to continue leading.","Closing conditions include shareholder approvals, SEC S-4 effectiveness, Nasdaq listing; target by Sep 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":262660000.00000003,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129047,"accession_number":"0001213900-25-118043","cik":2070887,"company_name":"Crown Reserve Acquisition Corp. I","ticker":"CRAC","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Crown Reserve Acquisition announces separate trading of shares, warrants, rights from Dec 9, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of CRACU units may elect to separate into Class A shares (CRAC), warrants (CRACW), and rights (CRACR) starting Dec 9, 2025.","Units not separated will continue trading on Nasdaq under CRACU; separated components will trade under symbols CRAC, CRACW, and CRACR.","Separation requires holders to contact broker and VStock Transfer, the company's transfer agent.","This announcement does not affect the SPAC's business combination timeline or terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":262660000.00000003,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129046,"accession_number":"0001213900-25-108750","cik":2070887,"company_name":"Crown Reserve Acquisition Corp. I","ticker":"CRAC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Crown Reserve Acquisition Corp. I closes $172.5M SPAC IPO on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 17.25M units at $10/unit; gross proceeds $172.5M including full exercise of over-allotment.","Units trade on Nasdaq under CRACU; each unit consists of one ordinary share, half warrant, and one right.","Trust account funded with ~$172.5M ($10/unit); funds available for initial business combination within 12 months.","Management led by CEO Prashant Patel and CFO Eric Sherb; board includes four independent directors.","Business combination focus on pharma, medical technology, and healthcare IT industries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":262660000.00000003,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}